Form 4: Dermata Therapeutics Grants Stock Options to Senior VP

Dermata Therapeutics, Inc. granted 18,000 stock options to Senior VP and CDO Christopher J. Nardo with an exercise price of $2.18.

Summary

• Christopher J. Nardo, Senior VP and Chief Development Officer (CDO) of Dermata Therapeutics, Inc. (DRMA), was granted 18,000 stock options.
• The options have an exercise price of $2.18 per share.
• The grant date for these options was January 2, 2026.
• The options will vest as to 25% upon the 12-month anniversary of the grant date (January 2, 2027).
• The remaining 75% will vest in 36 equal monthly installments commencing on the 12-month anniversary of the grant date.
• The expiration date for these stock options is January 1, 2036.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event (stock option grant), which is generally neutral to slightly positive as it aligns management incentives with shareholder interests without indicating immediate operational or financial performance changes.

Positives

• The grant of stock options aligns the interests of Senior VP and CDO Christopher J. Nardo with those of shareholders, incentivizing long-term performance and value creation.
• This is a standard form of executive compensation designed to attract, retain, and motivate key management personnel.

Negatives

• The exercise of these options in the future could lead to a slight dilution of existing shareholders' equity, although this is a common aspect of equity compensation plans.

Risks

• The value of the stock options is subject to the future market price of Dermata Therapeutics, Inc. common stock, which may fluctuate.
• The options are subject to vesting conditions, meaning they may not be fully exercisable if employment terms are not met.
• Potential dilution for existing shareholders if and when the options are exercised and converted into common stock.

Future Outlook

The stock option grant serves as a future incentive for Christopher J. Nardo, aligning his long-term performance with the company's success and shareholder value creation, subject to the specified vesting schedule.

Industry Context

The granting of stock options to senior executives is a common practice in the biotechnology and pharmaceutical industries, used to incentivize leadership, align their interests with shareholders, and retain talent in a competitive market.

Comparison to Industry Standards

• The use of stock options as a component of executive compensation is a widely accepted practice across the biotech and pharmaceutical sectors, consistent with global benchmarks for incentivizing management.
• The vesting schedule, which includes an initial cliff vesting followed by monthly installments, is a standard mechanism to encourage long-term commitment and performance, comparable to practices at similar-stage companies in the industry.

Related Party Transactions

• The grant of 18,000 stock options to Christopher J. Nardo, a Senior VP and CDO, constitutes a related party transaction between the company and an executive officer.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from incentivized management performance.
• Employees (specifically Christopher J. Nardo): Receives equity-based compensation, aligning personal financial interests with company growth.

Next Steps

• Christopher J. Nardo will continue to hold the granted stock options, subject to the specified vesting schedule.
• The options will become exercisable in accordance with the vesting terms, starting on January 2, 2027.

Key Dates

Keywords

Dermata Therapeutics, DRMA, stock option, executive compensation, insider transaction, Form 4, Christopher J. Nardo, equity incentive, vesting